Chelation therapy for cardiovascular disease; statins and kidney injuries; chlorthalidone for hypertension; and FDA actions.
The FDA has approved a fixed combination of doxylamine succinate and pyridoxine for the treatment of nausea and vomiting due to pregnancy. This is a reintroduction of a product widely used between 1956 and 1983.
Use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes in stable patients with a history of myocardial infarction (MI). These results do not support the routine use of chelation therapy for treatment of patients who have had a prior MI.
This meta-analysis did not convincingly demonstrate a positive effect of gastric acid-suppressing treatment in patients with chronic cough.
